↓ Skip to main content

Dove Medical Press

Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway

Overview of attention for article published in OncoTargets and therapy, November 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter
2 X users
reddit
1 Redditor

Readers on

mendeley
11 Mendeley
Title
Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway
Published in
OncoTargets and therapy, November 2018
DOI 10.2147/ott.s173008
Pubmed ID
Authors

Hui Chen, Qiang Zhang, Yu Zhang, Bin Jia, Bin Zhang, Changli Wang

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 11 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 18%
Student > Bachelor 2 18%
Student > Doctoral Student 1 9%
Student > Ph. D. Student 1 9%
Professor > Associate Professor 1 9%
Other 0 0%
Unknown 4 36%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 27%
Chemistry 2 18%
Medicine and Dentistry 2 18%
Unknown 4 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2018.
All research outputs
#16,143,374
of 25,809,966 outputs
Outputs from OncoTargets and therapy
#878
of 3,024 outputs
Outputs of similar age
#206,139
of 365,813 outputs
Outputs of similar age from OncoTargets and therapy
#47
of 146 outputs
Altmetric has tracked 25,809,966 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,024 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,813 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 146 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.